List of Excipients in Branded Drug ERGOMAR

Generic Drugs Containing ERGOMAR

Company	Ingredient	NDC	Excipient
Rosedale Therapeutics	ergotamine tartrate	10802-1202	ALUMINUM OXIDE
Rosedale Therapeutics	ergotamine tartrate	10802-1202	CELLULOSE, MICROCRYSTALLINE
Rosedale Therapeutics	ergotamine tartrate	10802-1202	CROSPOVIDONE
Rosedale Therapeutics	ergotamine tartrate	10802-1202	D&C YELLOW NO. 10
Rosedale Therapeutics	ergotamine tartrate	10802-1202	FD&C BLUE NO. 1
Rosedale Therapeutics	ergotamine tartrate	10802-1202	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in ERGOMAR?

# Of NDCs	Excipient
3	ALUMINUM OXIDE
3	CELLULOSE, MICROCRYSTALLINE
3	CROSPOVIDONE
3	D&C YELLOW NO. 10
3	FD&C BLUE NO. 1
3	MAGNESIUM STEARATE

Last updated: August 31, 2026

Ergomar is a legacy 2 mg sublingual ergotamine tartrate product with limited apparent patent protection and a narrow but identifiable excipient opportunity. The strongest commercial strategy is a low-risk reformulation focused on rapid sublingual disintegration, improved taste, moisture stability, lactose reduction or removal, and manufacturing robustness. A new excipient composition alone may not create durable exclusivity, but it can support an ANDA, a 505(b)(2) application, private-label supply, or a differentiated migraine product if the formulation produces measurable clinical or pharmacokinetic benefits.

Ergomar Excipient Strategy and Commercial Opportunities for Ergotamine Tartrate

What is Ergomar and how does its dosage form affect excipient strategy?

Ergomar is a 2 mg sublingual tablet containing ergotamine tartrate. The product is indicated for the acute treatment of migraine attacks, with or without aura, in adults. It is administered under the tongue rather than swallowed, making tablet wetting, rapid disintegration, dissolution, taste, and mucosal tolerability central formulation issues (FDA, 2023a).

Sublingual delivery can reduce reliance on gastrointestinal absorption, which is commercially relevant in migraine because nausea, vomiting, delayed gastric emptying, and poor oral intake can limit conventional oral tablets. Ergomar’s formulation strategy therefore needs to preserve three characteristics:

1. Rapid release in a small volume of saliva.
2. Acceptable mouthfeel and taste.
3. Physical and chemical stability during storage and handling.

The product’s key formulation constraint is the pharmacology of ergotamine. Ergotamine is a potent vasoconstrictor with clinically important contraindications and drug interactions. A formulation that increases absorption rate or systemic exposure may create regulatory and safety issues rather than provide a commercial advantage. Controlled and reproducible dissolution is more valuable than maximum release speed.

What excipients are relevant to an Ergomar reformulation?

The exact qualitative and quantitative composition of the marketed product should be established from the current FDA-approved labeling and regulatory filings before development. The relevant excipient classes for a 2 mg sublingual tablet are as follows:

Excipient function	Candidate materials	Commercial purpose
Filler and mouthfeel	Mannitol, lactose, microcrystalline cellulose	Tablet mass, compressibility, cooling sensation
Binder	Povidone, low-substituted hydroxypropyl cellulose	Mechanical strength and granule integrity
Superdisintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Rapid tablet breakup in saliva
Lubricant	Magnesium stearate, stearic acid, sodium stearyl fumarate	Ejection and manufacturing control
Sweetener	Sucralose, acesulfame potassium, saccharin sodium	Taste correction
Flavor	Mint, citrus, berry, or flavor-masking systems	Reduction of ergotamine bitterness
Wetting agent	Poloxamer, polysorbate, or selected surfactants	Improved wetting and dissolution
Moisture-control aid	Colloidal silicon dioxide, low-moisture excipient grades	Flow and stability
Film or taste barrier	Water-soluble polymer coating	Reduced contact with bitter drug particles

Mannitol is commercially attractive because it provides a low-hygroscopic, cooling mouthfeel that is common in orally disintegrating and sublingual products. Lactose can provide cost-effective tablet bulk but may be less attractive for a differentiated product positioned as lactose-free. Povidone and crospovidone can improve tablet integrity and disintegration, but their levels must be controlled because excessive binder can slow release while excessive superdisintegrant can impair hardness and friability.

Magnesium stearate deserves particular attention. Hydrophobic lubrication can slow wetting and dissolution in a sublingual tablet. Sodium stearyl fumarate or a lower lubricant concentration may improve early dissolution, although the effect must be demonstrated through comparative dissolution and stability studies.

What formulation patents could protect an Ergomar product?

A broad claim to ergotamine tartrate in a sublingual tablet is unlikely to provide strong new protection because the active ingredient and dosage form are established. More defensible claim categories would focus on a specific formulation architecture or measurable performance result.

Potential patent claim categories

Claim category	Example commercial concept	Expected patent strength
Excipient composition	Ergotamine tartrate with defined mannitol, crospovidone, binder, and lubricant ranges	Moderate if supported by unexpected results
Dissolution profile	Defined percentage released at early sublingual time points	Moderate, subject to enablement and obviousness
Taste-masking system	Polymer-coated drug particles or ion-exchange complex	Moderate to strong if technically differentiated
Moisture-stable tablet	Low-water-activity composition with defined packaging system	Moderate
Manufacturing process	Direct compression or dry granulation with controlled content uniformity	Moderate if process solves a reproducible problem
Device-packaging combination	Unit-dose moisture-barrier blister with protected sublingual tablet	Moderate, usually narrow
Method of use	Faster onset or use in patients unable to swallow	Weak to moderate unless supported by clinical data

The most credible formulation patent would combine composition and performance limitations. A patent claiming only a list of conventional excipients in routine concentration ranges would face a substantial obviousness risk under 35 U.S.C. Section 103.

A stronger application could claim a low-dose blend that maintains content uniformity, disintegrates within a defined period, achieves a defined early dissolution profile, and remains stable under accelerated conditions. Comparative data against the marketed Ergomar composition would be important.

How should an Ergomar excipient program address taste and sublingual tolerability?

Ergotamine can create a strong bitter or unpleasant oral sensation. Taste masking is therefore a practical commercial opportunity, particularly for patients who hold the tablet under the tongue during an acute migraine episode.

A formulation program should compare:

• Mannitol-based tablets with high-intensity sweeteners.
• Polymer-coated ergotamine particles.
• Drug-resin complexes.
• Effervescent or rapidly wetting matrices.
• Low-mass tablets with a thin water-soluble taste barrier.
• Flavor systems designed to minimize bitterness rather than simply add sweetness.

A complete taste strategy must evaluate the first seconds of contact, not only the residual aftertaste. Sublingual products cannot rely on a conventional swallowed film coat that delays drug release. Any coating must dissolve rapidly or selectively reduce taste exposure without materially slowing absorption.

Commercial differentiation is strongest if improved taste is paired with a shorter disintegration time, lower tablet mass, or improved packaging convenience.

What FDA regulatory pathway applies to an Ergomar reformulation?

A substantially equivalent generic sublingual tablet would generally be developed through an abbreviated new drug application under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, subject to FDA’s product-specific requirements and applicable general guidance (FDA, 2023b).

A materially different formulation may require a 505(b)(2) application. That pathway could be appropriate for:

• A new excipient system with a different release profile.
• A new sublingual or buccal delivery platform.
• A new dosage strength or presentation.
• A taste-masked product with supporting clinical or pharmacokinetic data.
• A combination with a delivery device or specialized packaging system.

The regulatory value of a 505(b)(2) strategy depends on whether the proposed formulation changes create a clinically relevant benefit. A minor excipient substitution that does not change performance may be more efficiently pursued through an ANDA.

New excipients would increase regulatory burden. Established excipients with relevant FDA Inactive Ingredient Database precedent are more practical, but the precedent must match the route, dosage form, concentration, and maximum daily exposure (FDA, 2024).

What is the Orange Book and patent status of Ergomar?

Ergomar is an old small-molecule product, not a biologic. Biosimilar risk is therefore not relevant. Competitive risk comes from generic ergotamine products, alternative migraine medicines, and reformulated 505(b)(2) products.

Public FDA Orange Book records should be used to confirm the current reference listed drug, marketing status, listed patents, and exclusivity. Ergomar’s age makes active new-drug exclusivity unlikely. No material commercial strategy should assume patent protection without a current Orange Book review and a separate USPTO search.

Exclusivity issue	Ergomar assessment
New chemical entity exclusivity	Expired
Pediatric exclusivity	No current commercial relevance identified
Orphan-drug exclusivity	Not the primary protection mechanism
Biosimilar exclusivity	Not applicable
Formulation patent opportunity	Possible for a new product, not presumed for legacy Ergomar
Method-of-use patent opportunity	Narrow and difficult to sustain without clinical differentiation
Orange Book-listed patent exposure	Must be verified against the current FDA listing
Paragraph IV risk	Relevant to any ANDA referencing an active listed patent; no current challenge should be assumed without docket evidence

When does Ergomar lose exclusivity and when could generic entry occur?

The original Ergomar exclusivity period expired decades ago. Generic entry is therefore legally possible if an applicant can satisfy FDA requirements and obtain approval. The practical timing depends on product availability, reference-product sourcing, bioequivalence complexity, manufacturing economics, and commercial demand.

Potential launch scenarios include:

Scenario	Product strategy	Commercial timing
Standard generic	Same active ingredient, strength, route, and dosage form	Fastest pathway if reference supply and bioequivalence are manageable
Excipient-optimized generic	Improved disintegration, taste, or stability	Moderate development timeline; may still fit ANDA requirements
505(b)(2) reformulation	New delivery performance or clinical positioning	Longer development and regulatory timeline
Private-label supply	Contract-manufactured Ergomar-equivalent product	Dependent on approved manufacturing capacity
Combination migraine product	Ergotamine paired with another active ingredient	Highest regulatory and clinical complexity

The most immediate opportunity is a reliable generic or authorized-style supply product. The best margin opportunity is a differentiated reformulation with a defensible formulation patent and evidence of improved patient handling.

Which companies are challenging Ergomar and what is the competitive landscape?

The competitive landscape is broader than direct ergotamine generics. Migraine treatment includes triptans, gepants, ditans, nonprescription analgesics, nasal products, injectable products, and fixed-dose combinations.

Direct competitive pressure comes from:

• Generic ergotamine tartrate products.
• Dihydroergotamine nasal and injectable products.
• Triptans such as sumatriptan, rizatriptan, and zolmitriptan.
• Gepants such as ubrogepant, rimegepant, and zavegepant.
• Nonprescription acetaminophen, NSAIDs, and combination analgesics.
• Digital and device-enabled acute migraine delivery systems.

Ergomar’s commercial advantages are sublingual administration and a long-established active ingredient. Its disadvantages include vasoconstrictive safety restrictions, interaction risks, limited suitability for some cardiovascular patients, and competition from newer non-vasoconstrictive therapies.

A reformulated product would need a clear market position. "Faster dissolution" alone may not overcome the availability of newer agents. "Lower cost, improved taste, unit-dose packaging, and dependable supply" is a more credible generic-market proposition.

What manufacturing and IP barriers affect an Ergomar excipient opportunity?

The principal manufacturing barriers are low-dose content uniformity, tablet robustness, rapid disintegration, lubricant control, and moisture protection. Ergotamine tartrate is present at a low nominal strength relative to tablet excipients, which increases the risk of segregation and assay variability.

A development program should prioritize:

• Geometric dilution or controlled granulation for content uniformity.
• Direct compression only after confirming powder-flow and segregation performance.
• Low-shear blending to limit demixing.
• Tight control of tablet weight and hardness.
• Dissolution testing in low-volume media representative of sublingual conditions.
• Moisture-barrier unit-dose packaging.
• Extractables and leachables assessment for blister materials.
• Stability testing for assay, degradation products, hardness, friability, and dissolution.

The IP barrier is less likely to be the legacy active ingredient than the formulation process, particle engineering, packaging, or clinical performance claim. A freedom-to-operate review should cover ergotamine compositions, orally disintegrating tablets, taste-masking technologies, sublingual delivery systems, and packaging patents in the United States, Europe, Canada, and major generic markets.

What licensing deals could support an Ergomar commercial product?

A licensing strategy could involve four asset types:

1. A formulation patent covering taste masking or rapid-release performance.
2. A contract manufacturing agreement with sublingual-tablet capability.
3. A packaging license for high-barrier unit-dose blister systems.
4. A distribution or private-label agreement with a migraine-focused pharmaceutical company.

The most valuable deal structure would link milestone payments to formulation selection, FDA filing, approval, and commercial launch. A simple excipient license without manufacturing know-how or comparative performance data would have limited value.

Potential counterparties include generic manufacturers, specialty pharmaceutical companies, contract development and manufacturing organizations, and migraine-focused distributors. Any deal should define ownership of formulation improvements, regulatory correspondence, stability data, manufacturing changes, and jurisdiction-specific patent rights.

How strong is the patent estate for an Ergomar excipient reformulation?

A legacy Ergomar patent estate is likely weak as a source of market exclusivity because the active ingredient and sublingual dosage form are old. A new formulation estate could be commercially useful but would probably be narrow.

Patent strength would improve if the applicant can show:

• A non-obvious excipient interaction.
• A reproducible early dissolution advantage.
• Better stability than the reference product.
• Reduced bitterness without delayed release.
• Improved content uniformity at the 2 mg dose.
• A clinically meaningful reduction in time to relief.
• A packaging system that solves a demonstrated moisture problem.

The strongest protection would combine composition, manufacturing process, dissolution performance, and a limited method-of-use claim. No single conventional excipient substitution is likely to support a broad exclusionary position.

Key Takeaways

• Ergomar is a 2 mg sublingual ergotamine tartrate tablet for acute migraine treatment.
• Its main excipient opportunities are rapid wetting, taste masking, low-dose content uniformity, moisture stability, and lactose reduction.
• Mannitol, crospovidone, povidone, alternative lubricants, sweeteners, and polymeric taste barriers are practical development candidates.
• The original product has no meaningful new-drug exclusivity remaining.
• Generic entry is legally possible, subject to FDA reference-product and bioequivalence requirements.
• A conventional excipient change is more suitable for an ANDA than a 505(b)(2) application.
• A 505(b)(2) strategy becomes more credible when the formulation produces clinically relevant onset, tolerability, or administration benefits.
• New formulation patents should claim defined composition ranges linked to dissolution, stability, taste, or manufacturing results.
• Biosimilar risk does not apply because Ergomar is a small-molecule drug.
• The strongest commercial opportunity is a reliable, better-tolerated, moisture-protected sublingual generic or a differentiated reformulation with narrow but defensible IP.

FAQs

Can a lactose-free Ergomar generic be commercially differentiated?

Yes. A lactose-free formulation could target patients and prescribers seeking excipient reduction, but the commercial benefit would be stronger if combined with improved taste, faster disintegration, or better supply reliability.

Is an orally disintegrating tablet equivalent to a sublingual Ergomar tablet?

Not automatically. Route-specific performance, dissolution, absorption, labeling, and bioequivalence requirements would determine whether FDA treats the product as pharmaceutically equivalent or as a materially different formulation.

Could a taste-masked Ergomar tablet receive new patent protection?

Yes, if the taste-masking system is novel, non-obvious, enabled, and supported by comparative data. A conventional sweetener or flavor addition alone would likely provide weak protection.

Is ergotamine a viable platform for a new migraine combination product?

It is technically possible, but the vasoconstrictive safety profile and interaction liabilities create significant clinical and regulatory constraints. A combination product would require a clear therapeutic rationale and careful exposure analysis.

What is the most attractive geographic market for an Ergomar reformulation?

The United States offers the clearest pathway through an ANDA or 505(b)(2) application, while European and other markets may offer opportunities where ergotamine access is limited or supply is inconsistent. Geographic prioritization should follow reference-product status, local demand, and patent clearance.

References

1. U.S. Food and Drug Administration. (2023a). Ergomar (ergotamine tartrate) sublingual tablets, prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023b). ANDA submissions: Content and format of an abbreviated new drug application. FDA.

3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Code, 21 U.S.C. § 355. New drugs.

6. Code of Federal Regulations, 21 C.F.R. Part 314. Applications for FDA approval to market a new drug.